Key Takeaways
- • Curewell Capital, a Los Angeles-based healthcare-focused private equity firm, has entered a definitive agreement to acquire a majority stake in ECA Medical from LongueVue Capital, according to a Business Wire release.
- • Terms of the transaction were not disclosed, though the partnership is designed to provide significant capital for ECA's expansion of its product portfolio, manufacturing facilities, and capabilities.
- • ECA, founded in 1979 and headquartered in Thousand Oaks, California, operates five FDA-registered, ISO 13485-certified facilities in California and Utah and has shipped more than 55 million instruments and 500,000 procedural kits worldwide.
- • Lane Hale will continue as President and CEO alongside the existing management team.
- • The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions.
Summary
ECA Medical, a designer and manufacturer of single-use instruments and surgery-ready solutions for the medical device industry, has announced a definitive agreement under which Curewell Capital will acquire a majority stake in the company from LongueVue Capital. According to the company's announcement distributed via Business Wire, the partnership is intended to accelerate ECA's expansion of its Surgery-Ready solutions. The terms of the transaction were not disclosed.
Founded in 1979, ECA is a vertically integrated supplier of surgery-ready solutions and systems, single-use procedural kits, and precision torque-limiting instruments for medical device original equipment manufacturers (OEMs). The company offers an end-to-end offering spanning concept, design, validation, manufacturing, sterilization, and packaging. ECA states it has shipped more than 55 million instruments and 500,000 procedural kits worldwide and operates five FDA-registered, ISO 13485-certified facilities in California and Utah.
Lane Hale, President and CEO, and the existing management team will continue to lead the company after the transaction. Hale said ECA is at an "inflection point" with strong demand from OEM partners and healthcare providers. Michael Dal Bello, Managing Partner at Curewell Capital, said ECA has set the standard in single-use medical instrumentation, with accelerating growth in procedural kits and surgery-ready solutions. Ceron Rhee, also a Managing Partner at Curewell, cited ECA's engineering culture and its work with OEMs of all sizes, and said supporting enabling technologies that enhance access, outcomes, and efficiency is central to Curewell's investment strategy.
Curewell describes itself as a middle-market healthcare investor focused on companies headquartered in North America, with experience across healthcare services, pharmaceutical services, medical devices, and healthcare technology. Solomon Partners acted as exclusive financial advisor and Norton Rose Fulbright LLP served as legal advisor to ECA and LongueVue Capital. Kirkland & Ellis LLP advised Curewell Capital. The transaction is expected to close in the fourth quarter of 2026.
Founded in 1979, ECA is a vertically integrated supplier of surgery-ready solutions and systems, single-use procedural kits, and precision torque-limiting instruments for medical device original equipment manufacturers (OEMs). The company offers an end-to-end offering spanning concept, design, validation, manufacturing, sterilization, and packaging. ECA states it has shipped more than 55 million instruments and 500,000 procedural kits worldwide and operates five FDA-registered, ISO 13485-certified facilities in California and Utah.
Lane Hale, President and CEO, and the existing management team will continue to lead the company after the transaction. Hale said ECA is at an "inflection point" with strong demand from OEM partners and healthcare providers. Michael Dal Bello, Managing Partner at Curewell Capital, said ECA has set the standard in single-use medical instrumentation, with accelerating growth in procedural kits and surgery-ready solutions. Ceron Rhee, also a Managing Partner at Curewell, cited ECA's engineering culture and its work with OEMs of all sizes, and said supporting enabling technologies that enhance access, outcomes, and efficiency is central to Curewell's investment strategy.
Curewell describes itself as a middle-market healthcare investor focused on companies headquartered in North America, with experience across healthcare services, pharmaceutical services, medical devices, and healthcare technology. Solomon Partners acted as exclusive financial advisor and Norton Rose Fulbright LLP served as legal advisor to ECA and LongueVue Capital. Kirkland & Ellis LLP advised Curewell Capital. The transaction is expected to close in the fourth quarter of 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.